Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
At the Presidential Symposium of the 2020 ESMO Annual Congress, results of a hea···【more】
Release date：2026-01-23Recommended：97
In December 2020, the U.S. Food and Drug Administration (FDA) accepted a supplem···【more】
Release date：2026-01-23Recommended：113
Pfizer recently announced that the Phase III CROWN study, which evaluates Lorbre···【more】
Release date：2026-01-23Recommended：117
Lorbrena (generic name: Lorlatinib) is a next-generation tyrosine kinase inhibit···【more】
Release date：2026-01-23Recommended：124
On November 19, 2020, Pfizer announced the positive results of the phase III hea···【more】
Release date：2026-01-23Recommended：93
Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) ···【more】
Release date：2026-01-23Recommended：112
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has a···【more】
Release date：2026-01-23Recommended：92
On January 28, 2022, Pfizer Inc. announced that the European Commission (EC) had···【more】
Release date：2026-01-23Recommended：91
At present, the core objective of research related to ponatinib is to improve it···【more】
Release date：2026-01-21Recommended：100
Patients should maintain a written list of all prescription drugs, over-the-coun···【more】
Release date：2026-01-21Recommended：93
This medicine may cause fluid retention and heart failure. If you experience rap···【more】
Release date：2026-01-21Recommended：92
Ponatinib exerts its therapeutic effect by inhibiting cancer cell proliferation ···【more】
Release date：2026-01-21Recommended：78
